News · 26 weeks75+433%
2026-03-012026-08-23
Mix6290d
- Insider44(71%)
- SEC Filings12(19%)
- Other2(3%)
- Earnings2(3%)
- Analyst1(2%)
- Dividends1(2%)
Latest news
25 items- SECSEC Form 144 filed by STERIS plc (Ireland)144 - STERIS plc (0001757898) (Subject)
- INSIDERSEC Form 4 filed by Director Shapiro Louis4 - STERIS plc (0001757898) (Issuer)
- INSIDERDirector Sohi Mohsen exercised 4,058 units of Ordinary Shares at a strike of $86.23 and sold $956,795 worth of Ordinary Shares (4,058 units at $235.78) (SEC Form 4)4 - STERIS plc (0001757898) (Issuer)
- INSIDERSEC Form 4 filed by Director Shah Nirav R4 - STERIS plc (0001757898) (Issuer)
- INSIDERSEC Form 4 filed by Director Martin Paul Edward4 - STERIS plc (0001757898) (Issuer)
- INSIDERSEC Form 4 filed by Director Boulud Pierre4 - STERIS plc (0001757898) (Issuer)
- INSIDERSEC Form 4 filed by Director Feldmann Cynthia L4 - STERIS plc (0001757898) (Issuer)
- INSIDERSEC Form 4 filed by Director Holland Christopher S4 - STERIS plc (0001757898) (Issuer)
- INSIDERSEC Form 4 filed by Director Alegria Esther M.4 - STERIS plc (0001757898) (Issuer)
- SECSEC Form 144 filed by STERIS plc (Ireland)144 - STERIS plc (0001757898) (Subject)
- SECSEC Form 10-Q filed by STERIS plc (Ireland)10-Q - STERIS plc (0001757898) (Filer)
- SECSEC Form 8-K filed by STERIS plc (Ireland)8-K - STERIS plc (0001757898) (Filer)
- SECAmendment: STERIS plc (Ireland) filed SEC Form 8-K: Leadership Update8-K/A - STERIS plc (0001757898) (Filer)
- SECSTERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits8-K - STERIS plc (0001757898) (Filer)
- PRSTERIS Announces Financial Results for Fiscal 2027 First QuarterFiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share increased to $2.59Targeted restructuring plan announced associated with new Formulated Chemistries Center of Excellence in North Carolina DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2027 first quarter ended June 30, 2026. Total revenue for the first quarter of fiscal 2027 increased 7% to $1.5 billion compared with $1.4 billion in the first quarter of fiscal 2026. Constant currency organic re
- PRSTERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina• This Formulated Chemistries Center of Excellence will support sterilization and disinfection for the global Healthcare and Pharmaceutical industries • This strategic manufacturing investment is the largest in STERIS’s history in a single site • New 600,000 square foot campus will create 335 jobs in North Carolina DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced that it will be investing $600 million to build a formulated chemistries manufacturing and distribution Center of Excellence in North Carolina, near the Raleigh-Durham Research Triangle region. The facility will serve as a central hub to produce high-performan
- PRSTERIS Raises Dividend to $0.69 per shareDUBLIN, IRELAND, July 30, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.69 per share. This represents a $0.06 increase in the dividend and the Company’s 21st consecutive year of dividend growth. The dividend is payable on September 25, 2026, to shareholders of record at the close of business on September 4, 2026. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE H
- ANALYSTUBS initiated coverage on Steris with a new price targetUBS initiated coverage of Steris with a rating of Buy and set a new price target of $275.00
- PRSTERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026DUBLIN, IRELAND, July 27, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2027 first quarter results at 9:00 a.m. ET on August 6, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on August 5, 2026. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on August 6, 2026, either at ww
- INSIDERDirector Sohi Mohsen exercised 3,781 units of Ordinary Shares at a strike of $71.40 and covered exercise/tax liability with 1,837 units of Ordinary Shares, increasing direct ownership by 9% to 24,305 units (SEC Form 4)4 - STERIS plc (0001757898) (Issuer)
- SECSEC Form 11-K filed by STERIS plc (Ireland)11-K - STERIS plc (0001757898) (Filer)
- INSIDERSr. VP, Gen Counsel, and Sec. Zangerle John Adam sold $296,968 worth of Ordinary Shares (1,419 units at $209.28), decreasing direct ownership by 4% to 35,259 units (SEC Form 4)4 - STERIS plc (0001757898) (Issuer)
- SECSEC Form 144 filed by STERIS plc (Ireland)144 - STERIS plc (0001757898) (Subject)
- INSIDERSr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 401 units of Ordinary Shares, decreasing direct ownership by 1% to 36,678 units (SEC Form 4)4 - STERIS plc (0001757898) (Issuer)
- INSIDERV.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 65 units of Ordinary Shares, decreasing direct ownership by 1% to 6,194 units (SEC Form 4)4 - STERIS plc (0001757898) (Issuer)
STE FAQ
6 questionsWhat does STERIS plc (Ireland) do?
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services...Where does STE stock trade?
STERIS plc (Ireland) (STE) is listed on NYSE.What sector and industry is STE in?
STERIS plc (Ireland) operates in the Health Care sector, Industrial Specialties industry.What are analysts saying about STE?
STERIS plc (Ireland) has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-07-28.What companies are similar to STE?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation), SNN (Smith & Nephew SNATS Inc.). Compare STE side-by-side with any of them on Quantisnow.How can I track STE on Quantisnow?
Quantisnow aggregates STERIS plc (Ireland)'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STE to receive live email and push alerts on every new disclosure.